

Tom Lesluyes

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8259125/publications.pdf>

Version: 2024-02-01

39
papers

1,126
citations

394421

19
h-index

454955

30
g-index

41
all docs

41
docs citations

41
times ranked

1450
citing authors

#	ARTICLE	IF	CITATIONS
1	<scp>CINSARC</scp> in high-risk soft tissue sarcoma patients treated with neoadjuvant chemotherapy: Results from the <scp>ISG&ST&S</scp> 1001 study. <i>Cancer Medicine</i> , 2023, 12, 1350-1357.	2.8	7
2	Signatures of copy number alterations in human cancer. <i>Nature</i> , 2022, 606, 984-991.	27.8	154
3	A pan-cancer compendium of chromosomal instability. <i>Nature</i> , 2022, 606, 976-983.	27.8	111
4	Expression and prognostic significance of PDGF ligands and receptors across soft tissue sarcomas. <i>ESMO Open</i> , 2021, 6, 100037.	4.5	8
5	ATRX Alteration Contributes to Tumor Growth and Immune Escape in Pleomorphic Sarcomas. <i>Cancers</i> , 2021, 13, 2151.	3.7	10
6	An integrative analysis of the age-associated multi-omic landscape across cancers. <i>Nature Communications</i> , 2021, 12, 2345.	12.8	54
7	E3 ubiquitin ligase HECTD2 mediates melanoma progression and immune evasion. <i>Oncogene</i> , 2021, 40, 5567-5578.	5.9	3
8	The Nanocind Signature Is an Independent Prognosticator of Recurrence and Death in Uterine Leiomyosarcomas. <i>Clinical Cancer Research</i> , 2020, 26, 855-861.	7.0	13
9	Impact of preoperative treatment on the CINSARC prognostic signature: translational research results from aPhaseA1 trial of the German Interdisciplinary Sarcoma Group (GISG 03). <i>Strahlentherapie Und Onkologie</i> , 2020, 196, 280-285.	2.0	1
10	A Global and Integrated Analysis of CINSARC-Associated Genetic Defects. <i>Cancer Research</i> , 2020, 80, 5282-5290.	0.9	8
11	Value of peri-operative chemotherapy in patients with CINSARC high-risk localized grade 1 or 2 soft tissue sarcoma: study protocol of the target selection phase III CHC-ST&S trial. <i>BMC Cancer</i> , 2020, 20, 716.	2.6	7
12	Specific immune landscapes and immune checkpoint expressions in histotypes and molecular subtypes of sarcoma. <i>Oncolimmunology</i> , 2020, 9, 1792036.	4.6	31
13	Cell-cell fusion of mesenchymal cells with distinct differentiations triggers genomic and transcriptomic remodelling toward tumour aggressiveness. <i>Scientific Reports</i> , 2020, 10, 21634.	3.3	9
14	LIX1 regulates YAP activity and controls gastrointestinal cancer cell plasticity. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 9244-9254.	3.6	11
15	Genome remodeling upon mesenchymal tumor cell fusion contributes to tumor progression and metastatic spread. <i>Oncogene</i> , 2020, 39, 4198-4211.	5.9	19
16	Tetraploidization of Immortalized Myoblasts Induced by Cell Fusion Drives Myogenic Sarcoma Development with DMD Deletion. <i>Cancers</i> , 2020, 12, 1281.	3.7	4
17	Genomic and transcriptomic comparison of post-radiation versus sporadic sarcomas. <i>Modern Pathology</i> , 2019, 32, 1786-1794.	5.5	25
18	Fusion-mediated chromosomal instability promotes aneuploidy patterns that resemble human tumors. <i>Oncogene</i> , 2019, 38, 6083-6094.	5.9	23

#	ARTICLE	IF	CITATIONS
19	Recurrent DMD Deletions Highlight Specific Role of Dp71 Isoform in Soft-Tissue Sarcomas. <i>Cancers</i> , 2019, 11, 922.	3.7	13
20	Clinicopathologic and Molecular Features of a Series of 41 Biphenotypic Sinonasal Sarcomas Expanding Their Molecular Spectrum. <i>American Journal of Surgical Pathology</i> , 2019, 43, 747-754.	3.7	65
21	CINSARC signature as a prognostic marker for clinical outcome in sarcomas and beyond. <i>Genes Chromosomes and Cancer</i> , 2019, 58, 124-129.	2.8	23
22	RCBTB1 Deletion Is Associated with Metastatic Outcome and Contributes to Docetaxel Resistance in Nontranslocation-Related Pleomorphic Sarcomas. <i>Cancers</i> , 2019, 11, 81.	3.7	3
23	<i>GREB1</i> fusion transcript detected by RNA sequencing in a uterine tumor resembling ovarian sex cord tumor (UTROSCT): A novel <i>CTNNB1</i> rearrangement. <i>Genes Chromosomes and Cancer</i> , 2019, 58, 155-163.	2.8	30
24	Chemotherapy in localized soft tissue sarcoma: will we soon have to treat grade 1 tumors? Update on CINSARC performances. <i>Annals of Oncology</i> , 2019, 30, 153-155.	1.2	8
25	Genome profiling is an efficient tool to avoid the STUMP classification of uterine smooth muscle lesions: a comprehensive array-genomic hybridization analysis of 77 tumors. <i>Modern Pathology</i> , 2018, 31, 816-828.	5.5	46
26	The Role of the Anti-Aging Protein Klotho in IGF-1 Signaling and Reticular Calcium Leak: Impact on the Chemosensitivity of Dedifferentiated Liposarcomas. <i>Cancers</i> , 2018, 10, 439.	3.7	19
27	Alternative PDGFD rearrangements in dermatofibrosarcomas protuberans without PDGFB fusions. <i>Modern Pathology</i> , 2018, 31, 1683-1693.	5.5	56
28	Gastrointestinal stromal tumor enhancers support a transcription factor network predictive of clinical outcome. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E5746-E5755.	7.1	20
29	Validation of the Complexity INDEX in SARCOMAs prognostic signature on formalin-fixed, paraffin-embedded, soft-tissue sarcomas. <i>Annals of Oncology</i> , 2018, 29, 1828-1835.	1.2	30
30	Regulation of RNA polymerase III transcription during transformation of human IMR90 fibroblasts with defined genetic elements. <i>Cell Cycle</i> , 2018, 17, 605-615.	2.6	21
31	Vnn1 pantetheinase limits the Warburg effect and sarcoma growth by rescuing mitochondrial activity. <i>Life Science Alliance</i> , 2018, 1, e201800073.	2.8	24
32	The CINSARC signature as a prognostic marker for clinical outcome in multiple neoplasms. <i>Scientific Reports</i> , 2017, 7, 5480.	3.3	24
33	Recurrent <i>TRIO</i> Fusion in Nontranslocation-Related Sarcomas. <i>Clinical Cancer Research</i> , 2017, 23, 857-867.	7.0	41
34	Expression and role of TYRO3 and AXL as potential therapeutical targets in leiomyosarcoma. <i>British Journal of Cancer</i> , 2017, 117, 1787-1797.	6.4	30
35	Heterogeneity in sarcoma cell lines reveals enhanced motility of tetraploid versus diploid cells. <i>Oncotarget</i> , 2017, 8, 16669-16689.	1.8	15
36	RNA sequencing validation of the Complexity INDEX in SARCOMAs prognostic signature. <i>European Journal of Cancer</i> , 2016, 57, 104-111.	2.8	66

#	ARTICLE	IF	CITATIONS
37	Heterogeneous Mechanisms of Secondary Resistance and Clonal Selection in Sarcoma during Treatment with Nutlin. PLoS ONE, 2015, 10, e0137794.	2.5	12
38	Differential motif enrichment analysis of paired CHIP-seq experiments. BMC Genomics, 2014, 15, 752.	2.8	23
39	Genome-wide <i>in silico</i> prediction of gene expression. Bioinformatics, 2012, 28, 2789-2796.	4.1	50